How many drugs treat Acute Bacterial Sinusitis?

Drug Landscape tracks 10 marketed treatments for Acute Bacterial Sinusitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-bacterial-sinusitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acute Bacterial Sinusitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Bacterial Sinusitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute Bacterial Sinusitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Test formulation (Treatment A)	test-formulation-treatment-a	Pfizer	Enzyme inhibitor	Specific enzyme	Not yet determined
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 8 drugs in Acute Bacterial Sinusitis
· 5 drugs in Acute Bacterial Sinusitis
GSK · 3 drugs in Acute Bacterial Sinusitis
Bayer AG · 2 drugs in Acute Bacterial Sinusitis
Bristol-Myers Squibb · 1 drug in Acute Bacterial Sinusitis
Bulovka Hospital · 1 drug in Acute Bacterial Sinusitis
Dr Reddys Labs Inc · 1 drug in Acute Bacterial Sinusitis
Generic (originally Abbott/AbbVie) · 1 drug in Acute Bacterial Sinusitis
Generic (originally Abbott/Lilly) · 1 drug in Acute Bacterial Sinusitis
Generic (originally Beecham/GSK) · 1 drug in Acute Bacterial Sinusitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Acute Bacterial Sinusitis
Generic (originally Pfizer) · 1 drug in Acute Bacterial Sinusitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute Bacterial Sinusitis:

Cite this brief

Drug Landscape (2026). Acute Bacterial Sinusitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-bacterial-sinusitis. Accessed 2026-06-10.

Acute Bacterial Sinusitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing